Xiaoling Tong

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Zhe Yang, Nong Yang, Qiuxiang Ou et al. · Clinical Cancer Research · 2018 · 531 citations

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

Yongqian Shu, Xue Wu, Xiaoling Tong et al. · Scientific Reports · 2017 · 256 citations · Full text

Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer

Lin Tong, Ning Ding, Xiaoling Tong et al. · Theranostics · 2019 · 117 citations · Full text

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC

Kai Chen, Fei Zhou, Wenxiang Shen et al. · Journal of Thoracic Oncology · 2017 · 90 citations

Advanced Nsclc, Sclerostin, Acquired Resistance +7

Variability of <i>EGFR</i> exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

Yanru Qin, Hong Jian, Xiaoling Tong et al. · Molecular Oncology · 2020 · 76 citations · Full text

Pathology, Egfr Inhibitors, Divergent Responses +17